Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors.

Abstract

Despite advances in the development of molecularly targeted therapies, limited improvements in overall survival have been noted among many cancer patients with solid tumors, primarily due to development of drug resistance. Accordingly, there is an unmet need for new targeted therapies and treatment approaches for cancer, especially for overcoming resistance. Expression of the folate receptor is upregulated in many tumor types and thus represents an ideal target for cancer treatment. Several folate receptor targeted therapies are in development, including the small molecule drug conjugate vintafolide, the monoclonal antibody farletuzumab, and the antibody-drug conjugate IMGN853. The role of the folate receptor as a target in cancer progression and resistance as well as emerging preclinical and clinical data from studies on those folate receptor targeted agents that are in development with a focus on vintafolide are reviewed. The folate receptor has several unique properties, such as high expression in several tumor types, that make it a rational target for cancer treatment, and allow for selective delivery of folate receptor targeted agents. Early-stage clinical data in lung and ovarian cancer suggest that vintafolide has the potential for combination with other standard approved agents.

• Authors: Ignace Vergote, Christopher P Leamon
• Journal: Therapeutic advances in medical oncology (Ther Adv Med Oncol) Vol. 7 Issue 4 Pg. 206-18 (Jul 2015) ISSN: 1758-8340 [Print] England
• PMID: 26136852 (Publication Type: Journal Article, Review)